Welcome to our dedicated page for Bolt Biotherapeutics news (Ticker: BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics stock.
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) is a clinical-stage biopharma leader developing novel cancer immunotherapies through its proprietary Boltbody ISAC platform. This page provides investors and researchers with essential updates on clinical trials, strategic collaborations, and therapeutic innovations in immuno-oncology.
Our curated news collection offers immediate access to official press releases and verified developments. Users can track progress across three key areas: clinical trial milestones for solid tumor treatments, research partnerships advancing myeloid-targeted therapies, and platform enhancements to the Boltbody ISAC technology.
All content undergoes rigorous verification to ensure compliance with financial disclosure standards. The resource is particularly valuable for monitoring BOLT's progress in activating both innate and adaptive immune responses through targeted antibody conjugates.
Bookmark this page for streamlined access to BOLT's evolving position in cancer immunotherapy. For comprehensive analysis of how these developments impact therapeutic pipelines and investment considerations, consult your financial advisor.
Bolt Biotherapeutics (BOLT) announced promising results from its Phase 1 dose-escalation study of BDC-3042, a novel immunotherapy for cancer treatment, at the AACR Annual Meeting 2025. The study enrolled 17 patients across seven dose cohorts with various tumor types.
Key findings include:
- BDC-3042 was well-tolerated up to 10 mg/kg q2w with no dose-limiting toxicities
- No drug-related serious adverse events or treatment discontinuations reported
- Most common drug-related adverse events: fatigue, flatulence, and nausea (12% each)
- Demonstrated favorable pharmacokinetics and biological activity
- Showed anti-tumor activity, including an unconfirmed partial response in NSCLC
- 80% of evaluable patients achieved stable disease or better
The company is now seeking partnership opportunities to advance BDC-3042's development, particularly focusing on NSCLC and post-immunotherapy settings.
Bolt Biotherapeutics (BOLT) announced it will present data from its Phase 1 dose-escalation clinical study of BDC-3042 at the AACR Annual Meeting in Chicago (April 25-30, 2025). BDC-3042 is a pioneering agonist antibody targeting dectin-2, specifically designed for patients with advanced cancers including non-small cell lung cancer (NSCLC).
The company will showcase three poster presentations: the first-in-human dose-escalation study results of BDC-3042, presented by Dr. Ecaterina Dumbrava from MD Anderson Cancer Center, and two preclinical studies featuring their Boltbody™ ISAC technology targeting CEA and PD-L1. These presentations will highlight advancements in their immunotherapy pipeline for treating various cancers including colorectal, pancreatic, and lung tumors.
Bolt Biotherapeutics (NASDAQ: BOLT) reported its Q4 and full-year 2024 financial results, highlighting key developments in its cancer immunotherapy pipeline. The company maintains a strong cash position of $70.2 million, expected to fund operations through mid-2026.
Two major programs are advancing: BDC-4182, targeting claudin 18.2 for gastric cancer, is scheduled to begin clinical trials in Q2 2025. The BDC-3042 Phase 1 trial has completed enrollment in its highest dose cohort with no dose-limiting toxicities, with results expected in Q2 2025.
Financial highlights for 2024 include: collaboration revenue of $7.7 million, R&D expenses of $57.5 million (down from $61.5M in 2023), and G&A expenses of $18.5 million (reduced from $22.5M in 2023). The company reported an operational loss of $73.0 million for the full year.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company focused on cancer immunotherapies, has announced its participation in two major healthcare conferences this March. The company will deliver a presentation at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 3:10 p.m. EST. Additionally, Bolt's management team will engage in one-on-one meetings at the Leerink Partners Global Healthcare Conference on March 10, 2025.
Bolt Biotherapeutics (BOLT) announced that Caprin-1 is the target of their worldwide co-development collaboration with Toray Industries. The partners are developing a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) targeting Caprin-1, which is applicable to multiple solid tumor types.
Under the agreement, Toray provides proprietary antibodies targeting Caprin-1, including TRK-950, while Bolt contributes proprietary linker-payloads from its Boltbody™ ISAC platform. Caprin-1 is a tumor-specific antigen highly expressed on solid tumors with minimal presence in normal tissues, and contributes to tumor growth and metastases. Toray's TRK-950 antibody is currently in Phase 2 development for Gastric cancer.
Bolt Biotherapeutics (BOLT) reported Q3 2024 financial results, highlighting progress in its cancer immunotherapy programs. The company advanced to the highest dose level in BDC-3042's Phase 1 trial and presented updated preclinical data for BDC-4182 at SITC. Q3 revenue was $1.1 million, down from $2.5 million in Q3 2023. R&D expenses decreased to $13.8 million from $15.0 million, while G&A expenses reduced to $3.8 million from $5.8 million. The company reported an operational loss of $16.4 million. With $84.4 million in cash, funding is expected to last through mid-2026.
Bolt Biotherapeutics (BOLT) presented updated preclinical data for BDC-4182, their next-generation Boltbody™ ISAC targeting claudin 18.2, and findings from Phase 1 dose-escalation trial of BDC-1001 at SITC. BDC-4182 showed superior efficacy compared to claudin 18.2 ADCs in preclinical studies, demonstrating anti-tumor activity across various models and acceptable safety in non-human primates. The company plans to initiate clinical trials in 2025. The Phase 1 BDC-1001 trial revealed that greater immune activation was associated with clinical benefit, particularly in patients with high HER2 antigen expression, supporting the development of next-generation ISACs with enhanced immune activation.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company, has announced changes to its Board of Directors. Jakob Dupont, M.D., Executive Partner at Sofinnova Investments, has been appointed to the board, bringing over 20 years of experience in oncology and immuno-oncology. Concurrently, Dr. Jim Healy is stepping down as Lead Independent Director, Frank D. Lee is departing the board, and Brian O'Callaghan, CEO of Deep Genomics, will assume the role of Chair.
Dr. Dupont's extensive background includes leadership roles at Atara Biotherapeutics, Gossamer Bio, and Genentech/Roche, where he was instrumental in developing several successful cancer therapies. His appointment is expected to benefit Bolt's pipeline advancement and collaborations. The company is currently conducting a clinical trial with a first-in-class Dectin-2 agonist and has a near-clinical ISAC program targeting Claudin 18.2.
Bolt Biotherapeutics (BOLT), a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies, has announced its participation in two major conferences this September. The company will be featured in:
1. A fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024, at 7:00 a.m. EDT.
2. A company presentation at the H.C. Wainwright 26th Annual Global Investment Conference, available from September 9, 2024, at 7:00 a.m. EDT.
Both presentations will be accessible via webcast on Bolt's website, with replays available for 30 days after each event. This participation demonstrates Bolt's commitment to engaging with investors and showcasing its progress in the competitive field of cancer immunotherapy.
Bolt Biotherapeutics (Nasdaq: BOLT) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Advancement to cohort 6 in the Phase 1 study of BDC-3042 for advanced cancers.
2. Acceptance of an abstract for BDC-4182, a claudin 18.2-targeting Boltbody ISAC, at the SITC 39th Annual Meeting.
3. Cash balance of $97.5 million as of June 30, 2024, expected to fund operations through mid-2026.
4. Q2 2024 financial results: Collaboration revenue of $1.3 million, R&D expenses of $15.4 million, G&A expenses of $4.9 million, and a loss from operations of $22.6 million.
5. Ongoing collaborations with Genmab and Toray continue to progress.
FAQ
What is the current stock price of Bolt Biotherapeutics (BOLT)?
What is the market cap of Bolt Biotherapeutics (BOLT)?
